Antibody-guided drug works against acute lymphoblastic leukemia

Phase II study shows 61 percent response rate for patients with resistant or recurrent disease

2011-05-24

(Press-News.org) HOUSTON — An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

Patients enrolled in the trial led by investigators at The University of Texas MD Anderson Cancer Center had ALL that resisted other therapies or recurred after treatment.

"A response rate of more than 50 percent in this patient population probably makes inotuzumab ozogamicin the most active single-agent therapy ever for ALL," said Hagop Kantarjian, M.D., professor and chair of MD Anderson's Department of Leukemia and study senior investigator.

ALL is an aggressive form of leukemia in which immature white blood cells, called lymphoblasts, grow rapidly, crowding out normal blood cells.

The drug, also known as CMC-544, links an antibody that targets CD22, a protein found on the surface of more than 90 percent of ALL cells, and the cytotoxic agent calicheamicin. Once the drug connects to CD22, the ALL cell draws it inside and dies.

Response rate for other second options is 20-30 percent

Kantarjian said second-line chemotherapy combinations used for ALL typically have a complete response rate of 20-30 percent. The monoclonal antibody-based drug developed by Pfizer, Inc., also is the first of its type for ALL.

The drug is safe, said Elias Jabbour, M.D., assistant professor in MD Anderson's Department of Leukemia, who will present the study results at ASCO on Monday, June 6. Almost all side-effects were of low grade (1-2) and manageable. Drug-induced fever was the most common side effect, reaching higher grades in nine of 48 patients.

Out of 46 patients evaluable for response, nine had a complete response, 14 had complete response without full recovery of platelets, and 5 had less than 5 percent blasts in their bone marrow without blood count recovery.

Sixteen responders subsequently received a donor blood stem cell transplant, Jabbour noted.

Drug combinations

Combining inotuzumab with other chemotherapy might further improve ALL treatment, Jabbour said. MD Anderson has a phase II clinical trial under way following inotuzumab treatment with another monoclonal antibody drug, rituximab, currently used in some types of non-Hodgkin's lymphoma.

Rituximab targets the CD20 surface protein, which occurs in 50 percent of ALL cells.

In addition to combinations, the authors suggest that a shift from dosing every three weeks to weekly should be explored.

Frontline therapy for ALL is a combination chemotherapy regimen known as HyperCVAD.

The National Cancer Institute estimates that 5,330 people received an ALL diagnosis in 2010 and 1,420 died of the disease.

ALL is the most common type of childhood cancer. Combined chemotherapy regimens have raised long-term survival from 5 percent of pediatric patients in the 1960s to 85 percent today.

INFORMATION:

The clinical trial was funded by a grant from Pfizer.

Co-investigators with Jabbour and Kantarjian are Susan O'Brien, M.D., Deborah Thomas, M.D., Farhad Ravandi, M.D., Sergernne York, Monica Kwari, Stefan Faderl, M.D., Tapan Kadia, M.D., Guillermo Garcia-Manero, M.D., and Jorge Cortes, M.D., of MD Anderson's Department of Leukemia; Christopher Wilson and Robert Tarnai, of PPD, Inc.; and Anjali S. Advani, M.D., of the Cleveland Clinic Taussig Cancer Institute.

Kantarjian and co-author Cortes receive research funding from Pfizer, and Cortes has been a consultant to the company.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.

[Attachments] See images for this press release:

ELSE PRESS RELEASES FROM THIS DATE:

Study links acetaminophen to lower prostate cancer risk

2011-05-24

ATLANTA – May 23, 2011 – A new study from American Cancer Society researchers finds use of 30 tablets a month or more of acetaminophen for five or more years was associated with an estimated 38% lower risk of prostate cancer. The study appears in Cancer Epidemiology, Biomarkers and Prevention and is one of only two studies of prostate cancer to date that have examined the association with acetaminophen use that was both long-term and regular. Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), particularly long-term use, has been associated with modestly ...

Cover crop seeder pulls triple duty for small farms

2011-05-24

Farmers using a cover crop seeder developed by Penn State agricultural scientists may eventually need only a single trip across the field to accomplish what takes most farmers three passes and several pieces of equipment to do. Pennsylvania farmers are increasingly interested in growing cover crops, but the time, cost and late fall harvest of corn and other crops often limit their use, said Gregory Roth, professor of agronomy. The seeder can help farmers, especially small operations, save time and money by condensing multiple tasks into one trip through a no-till field. ...

New genetic testing technology for IVF embryos

2011-05-24

Researchers at the Johns Hopkins University School of Medicine have devised a new technique, which helps couples that are affected by or are carriers of genetic diseases have in vitro fertilized babies free of both the disease in question and other chromosomal abnormalities. The results were reported in the April issue of Fertility and Sterility. Because embryos are so small and cells contain too little DNA to do extensive testing, researchers have in the past had to limit genetic testing of IVF embryos to either looking for a specific gene mutation that is known to exist ...

NIH scientists identify most proteins made by parasitic worm

2011-05-24

A team led by Thomas B. Nutman, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has completed a large-scale analysis of most of the proteins produced by Brugia malayi, one kind of parasitic worm that causes lymphatic filariasis, or elephantiasis. The greatly swollen lower limbs that can result from chronic infection with this mosquito-borne parasite can be severely disabling. The investigators characterized 7,103 proteins produced in various stages of the worm's lifecycle, including male and female ...

'Top 5' list helps primary care doctors make wiser clinical decisions

2011-05-24

PHILADELPHIA -- A physician panel in the primary care specialty of internal medicine has identified common clinical activities where changes in practice could lead to higher quality care and better use of finite clinical resources. The study identifying the Top 5 list of internal medicine activities appears online in the Archives of Internal Medicine. "Our aim was to come up with a list of best practices via consensus from actual practitioners, said Jeffrey R. Jaeger, MD, FACP, associate professor of Internal Medicine in the Perelman School of Medicine at the University ...

Poorer reading skills following changed computer habits of children

2011-05-24

Sweden and the US are two countries in which increased leisure use of computers by children leads to poorer reading ability. This is the conclusion from research carried out at the University of Gothenburg, Sweden. Professor Monica Rosén of the Department of Education and Special Education has analysed differences between different countries over time in order to explain change in reading achievement among 9-10-year olds. Within the framework of the research project she and her colleagues have studied how pupils' reading skills have changed since 1970. Hungary, Italy, ...

'Young, disadvantaged men'

2011-05-24

Los Angeles, CA (May 23, 2011) With teen moms being debated heavily in popular culture today, it's easy to neglect the effects of fatherhood. However, recent research shows that young, disadvantaged men also affect a family and society. In fact, by age 30, between 68 and 75 percent of young men with a high school degree or less are fathers. A new issue of The Annals of the American Academy of Political and Social Science (published by SAGE) called "Young Disadvantaged Men: Fathers, Family, Poverty, and Policy," examines how poverty and lack of education are creating ...

Eggs, butter, milk -- memory is not just a shopping list

2011-05-24

Often, the goal of science is to show that things are not what they seem to be. But now, in an article which will be published in an upcoming issue of Perspectives on Psychological Science, a journal of the Association for Psychological Science, a veteran cognitive psychologist exhorts his colleagues in memory research to consult the truth of their own experience. "Cognitive psychologists are trying to be like physicists and chemists, which means doing controlled laboratory experiments, getting numbers out of them and explaining the numbers," says Douglas L. Hintzman, ...

Heredity behind subjective effects of alcohol

2011-05-24

Scientists have long known that people who have a close relative with alcohol problems themselves run an increased risk of starting to abuse alcohol. The reason for this has not been known, but a new study from the University of Gothenburg, Sweden, provides part of the answer. The study shows that people who have a close relative who is an alcoholic react more positively to alcohol than other people. The study has been published in the scientific journal Alcohol: Clinical & Experimental Research, and is the first to have investigated a large group of people who have a ...

Hubble views the star that changed the universe

2011-05-24

Though the universe is filled with billions upon billions of stars, the discovery of a single variable star in 1923 altered the course of modern astronomy. And, at least one famous astronomer of the time lamented that the discovery had shattered his world view. The star goes by the inauspicious name of Hubble variable number one, or V1, and resides in the outer regions of the neighboring Andromeda galaxy, or M31. But in the early 1900s, most astronomers considered the Milky Way a single "island universe" of stars, with nothing observable beyond its boundaries. Andromeda ...

LAST 30 PRESS RELEASES:

The Lancet: Billions lack access to healthy diets as food systems drive climate and health crises, but sustainable, equitable solutions are within reach, says new EAT-Lancet report